AETOSWire - AETOSWire

AETOSWire distributes your news swiftly across your target audiences to every corner of the world with the latest state-of-the-art technology and innovative solutions that give you the competitive edge you need to get ahead of the competition.

Address

Dubai Media City, Building 1, 3rd Floor, Office 312 P.O. Box 502342 Dubai, United Arab Emirates

+971 4 55 77 007

+971 4 55 77 008

info@aetoswire.com

Quick Links

About us

Services

Newsroom

My Account

Privacy
Terms Of Use
Sitemap

Your experience on this site will be improved by allowing cookies. Cookie Policy

NewsRoom

Boehringer Ingelheim

CORRECTION AND REPLACEMENT - Boehringer Ingelheim receives approval for SENVELGO®...

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone...

Boehringer Ingelheim’s SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best...

Phase III Studies to Investigate Survodutide for People Living with...

Boehringer Ingelheim and ZEISS join forces to early detect eye...

Boehringer Ingelheim receives SBTi validation for CO2 reduction targets

First half of 2023: Boehringer Ingelheim sees strong growth and...

Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial

Data shows nearly 19% weight loss in people with overweight...

Jardiance® recommended for the treatment of adults with chronic kidney...

Boehringer Ingelheim and Zealand Pharma announce phase II trial showed...

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic...

Search...

Search...